In the company’s news yesterday,
RXi Pharmaceuticals Corporation reported that it has hired Dr. Anastasia Khvorova to fill the new post of Chief Scientific Officer (CSO). RXi Pharmaceuticals expects to benefit from the six years of experience Khvorova gained in the development and supply of RNAi compounds in her last job as CSO of Dharmacon, Inc.
According to company President and CEO, Dr. Tod Woolf, Khvorova’s appointment adds to the scope and depth of RXi’s talent in the RNAi field. “Among her many accomplishments,” noted Woolf, “Dr. Khvorova’s group at Dharmacon designed and manufactured RNAi compounds targeting virtually all of the known human genes. Moreover, Dr. Khvorova is one of the most widely cited authors of research articles in the field of RNAi, which serves as a testament to the impact her work has had in the field. Through her ground-breaking research, Dr. Khvorova also developed “self-delivering” RNAi compounds in her previous role as CSO at Dharmacon.”
“I am pleased to be joining the exceptional team at RXi which includes a number of leaders in the field of RNAi. I believe that RXi is well positioned to successfully address the challenges in developing next generation RNAi therapeutics,” said Dr. Khvorova. Khvorova is a recognized expert in the RNAi field. She has obtained 30 patents, authored 150 abstracts, numerous book chapters, and more than 40 peer-reviewed articles.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
